AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00299104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT02088099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
Study NCT00299104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose
Study NCT01891396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid and TH (Cingal®)
Description: Injection into knee
Study NCT01891396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid (Monovisc®)
Description: Injection into knee
Study NCT01891396 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline placebo packaged to look identical to comparator syringes. Injection into knee.
Study NCT01995526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Study NCT01229046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticarcillin-clavulanic acid
Description: 5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
Study NCT02058004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Description: Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
Study NCT01304615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decrease Energy Density of the Diet
Description: Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
Study NCT01304615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease Energy Density of the Diet
Description: Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
Study NCT01304615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increase Steps per Day
Description: Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
Study NCT03375775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
Description: According to standardized clinical protocol
Study NCT03375775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No immunotherapy, symptomatic treatment
Description: These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
Study NCT01304615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Steps per Day
Description: Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
Study NCT01304615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumption of Self-made Meals
Description: Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
Study NCT03925103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D VATS lobectomy
Description: pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
Study NCT03925103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D VATS lobectomy
Description: pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
Study NCT02220192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal LEEP
Description: Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
Study NCT04512820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUCLEAR tissue removal system
Description: evacuation of POC using the TRUCLEAR tissue removal system
Study NCT01496053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AndoSan
Description: AndoSan 30 ml x 2 for 21 days
Study NCT02671760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: 2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
Study NCT02671760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01496053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sugar Extract
Description: Sham comparator
Study NCT03586024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: dose of pembrolizumab will be 200 mg IV every 3 weeks
Study NCT03616600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath-O-Correct Lens
Description: Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
Study NCT03274947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar TMS
Description: Cerebellar transcranial magnetic stimulation
Study NCT03274947 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar TMS
Description: Sham cerebellar transcranial magnetic stimulation
Study NCT02485509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500/Placebo
Description: VM-1500 or Placebo
Study NCT04146233 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Point of care gastric ultrasound
Description: Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).
Study NCT01651039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
Study NCT01651039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
Study NCT05351840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LivaloV
Description: Treatment A, Tablet, Oral, QD for 7 Days
Study NCT01651039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
Study NCT02453178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
Study NCT02453178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling
Description: The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
Study NCT01847274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Niraparib
Description: Niraparib vs placebo 2:1 ratio
Study NCT01847274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT05351840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Treatment B, Tablet, Oral, QD for 10 Days
Study NCT00830934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individual care
Description: The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
Study NCT00830934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: group care
Description: The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
Study NCT05771350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: online hemodiafiltration
Description: 20 patients on regular hemodialysis received online hemodiafiltration
Study NCT05771350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high flux hemodialysis
Description: 20 patients on regular hemodialysis received high flux hemodialysis
Study NCT05771350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low flux hemodialysis
Description: 20 patients on regular hemodialysis received low flux hemodialysis
Study NCT02641912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biotene mouthwash
Description: During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
Study NCT02641912 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mineral Water
Description: During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use.
Study NCT01651312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled YM178
Description: oral solution (1.85 MBq)
Study NCT03722316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Nature Video
Description: An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention.
Study NCT03722316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Nature Video
Description: An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention.
Study NCT03722316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Video
Description: This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention.
Study NCT03722316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral Video
Description: This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention.
Study NCT04244058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine + L-DOPA
Description: Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg
Study NCT04244058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NMDA blocker
Description: NMDA blocker
Study NCT04452318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933 + REGN10987
Description: Subcutaneous (SC) or Intramuscular (IM) injections
Study NCT04452318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC or IM injections
Study NCT01665768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.
Study NCT01665768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
Study NCT03459157 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HIV prevention package including PrEP
Description: All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
Study NCT04358289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community education
Description: Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
Study NCT02769819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible fiberscope
Description: * Characteristics of patients will be assessed before induction of general anesthesia~* Glottic visualization will be evaluated by direct laryngoscopy.~* The endotracheal tube will be loaded onto the scope after silicon spray lubrication~* Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~* With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~* Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation.
Study NCT02387242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single oral dose of rifampicin
Study NCT05351840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LivaloVA
Description: Treatment C, Tablet, Oral, QD for 7 Days
Study NCT03306472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 40 MG
Description: Progesterone Agonist
Study NCT03306472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 160 MG
Description: Progesterone Agonist
Study NCT03306472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Aromatase Inhibitor
Study NCT03306472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase Inhibitor
Study NCT01329341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service Dogs
Description: Service dogs will be trained to help Veterans with PTSD
Study NCT02089009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Retinal imaging
Description: Retinal imaging by using non-mydriatic camera devices
Study NCT01255293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1000 centistoke silicone oil
Description: Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
Study NCT02089009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vessel measurements
Description: Vessel measurements based on the taken images by the use of a specialized software
Study NCT02089009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Change in vessel diameters
Description: Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
Study NCT03703232 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational prosthetic foot
Description: Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
Study NCT03061877 — intervention group
Intervention type: OTHER
Intervention: Anxiety or depression
Description: The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
Study NCT02554786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate/Mometasone furoate
Study NCT02554786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Study NCT02554786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol xinafoate/fluticasone propionate
Study NCT02901522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
Study NCT02901522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry (baseline)
Description: Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
Study NCT02901522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry (baseline)
Description: Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
Study NCT02901522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry (20 - 22weeks)
Description: Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
Study NCT02901522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry (20 - 22weeks)
Description: Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
Study NCT02901522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: The general practioner received phone call to asthma care.
Study NCT03853161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vapotherm
Description: A form of non invasive ventilation used in newborns
Study NCT03853161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: A form of non invasive ventilation used in newborns
Study NCT04705675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education
Description: The mothers were asked to remember the pseudonyms they used on the pretest and to use the same pseudonym on the posttest. Following the pretest, the mothers in the study group were taken into a separate room at the FHC and asked to breastfeed their infants. The mothers' breastfeeding behaviors were observed. After the breastfeeding, each mother was provided an average 30-minute session of individual education. All of the mothers in the study group received the education from the same researcher. Both audio and visual materials were used in the mothers' training.
Study NCT03822234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified ileal conduit
Description: Modified ileal conduit (Extraperitonealization)
Study NCT02148185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study NCT03631238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.
Description: all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer.
Study NCT02773524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.